Lexicon Pharmaceuticals, Inc. (LXRX)
-NasdaqGS | Prev Close: | 2.89 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.55 - 3.18 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,094,180 |
|---|
| Market Cap: | 1.48B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Does Lexicon Own the Future of Type 2 Diabetes?at Motley Fool(Tue, Oct 1)
- Why Lexicon Pharmaceuticals Inc. Shares Exploded Higherat Motley Fool(Tue, Oct 1)
- Lexicon surges on diabetes drug study dataAP(Tue, Oct 1)
- On The Fly: Pre-market Moversat theflyonthewall.com(Tue, Oct 1)
- Lexicon soars on kidney-drug dataoptionMONSTER(Tue, Oct 1)
- LX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal ImpairmentPR Newswire(Tue, Oct 1)
- InPlay: Lexicon Pharma achieves 'positive' Results in Type 2 Diabetes Patients with Renal Impairment; LX4211 provided clinically meaningful and statistically significant reductionsBriefing.com(Tue, Oct 1)
- LEXICON PHARMACEUTICALS, INC./DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial StatementsEDGAR Online(Thu, Sep 19)
- Matthew Lehman, the CEO of Prima BioMed Ltd. (PBMD), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Sep 13)
- Lexicon Pharmaceuticals' CEO Presents at Morgan Stanley Global Healthcare Conference (Transcript)at Seeking Alpha(Wed, Sep 11)
- Lexicon To Present At The Stifel Nicolaus Healthcare ConferencePR Newswire(Fri, Sep 6)
- Lexicon To Present At The Morgan Stanley Global Healthcare ConferencePR Newswire(Thu, Sep 5)
- 3 Reasons Why Clinical Trials Failat Motley Fool(Thu, Aug 29)
- LEXICON PHARMACEUTICALS, INC./DE FinancialsEDGAR Online Financials(Thu, Aug 8)
- Lexicon To Present At The Wedbush PacGrow Life Sciences Management Access ConferencePR Newswire(Wed, Aug 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1,274.81 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.17 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 0.59 |
|---|
Business Summary
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has comple...
View More